Standard BioTools Holders Would Own About 16% Of Treeline Combination, Amended S-4 Shows
The second amended filing sets an exchange ratio range, a 12-seat board and a $2.5 billion Treeline value against $460 million for Standard BioTools.
Standard BioTools holders would own about 16% of the combined company after the all-stock reverse merger with Treeline Biosciences, with Treeline holders taking about 84% on a fully diluted basis, according to a second amended S-4 filed Friday. The amendment adds the estimated exchange ratio, pro forma financials and the combined company's governance.
The exchange ratio and the cash adjustment
The filing estimates 11.1202 to 11.7157 Standard BioTools shares for each Treeline share, before a reverse stock split. The pro forma ratio is 1:11.4101, at the midpoint of the $450 million to $475 million net cash range Standard BioTools expects at closing.
The ratio rests on a $2.5 billion equity value for Treeline against $460 million for Standard BioTools. The Standard BioTools figure falls if net cash at closing is below $449 million and rises if it is above $451 million.
A $12.5 million swing in net cash moves the share count by less than 1% of ownership, the filing says. Registration covers 364,223,328 shares, calculated at the high end of the range and before any reverse split.
After closing, Treeline can dispute the net cash figure within 30 days. A shortfall means extra shares for Treeline holders; a surplus goes to holders of the contingent value rights, which Standard BioTools would pay in stock, capped at 76,000,000 shares.
Cash, board and the catch for current holders
Combined cash is expected to top $900 million at closing, including about $450 million from Standard BioTools, with a runway into 2029. Net tangible book value falls from $1.38 per share before the merger to $0.43 after it, a decrease of $0.95 per share for Standard BioTools holders.
The board would have 12 seats: 10 Treeline designees and 2 from Standard BioTools, Thomas Carey and Kathy Hibbs. Joshua Bilenker would be chair and CEO, and the ticker would change from LAB to TRLN.
The filing says Standard BioTools' strategic review found no suitable life-sciences-tools acquisition and that the stand-alone plan was no longer viable. Treeline is a clinical-stage company with no revenue; its pipeline includes TLN-254, which had a partial FDA clinical hold imposed in June and lifted July 23.
A reverse split of between 1-for-20 and 1-for-40 is needed to meet Nasdaq's $4.00 minimum bid for listing; the ratio is still to be agreed by the two companies.
Legacy business sales and the deal's exits
Standard BioTools agreed to sell its mass cytometry business to Element Biosystems for $5.5 million in cash, a deal that needs both the merger and a stockholder vote. A separate microfluidics sale to ARCHIMED was signed October 4 and is not conditioned on the merger.
The merger can close even if either sale fails. Wind-down costs would reduce net cash, estimated at $7.5 million for mass cytometry and $6.4 million for microfluidics.
Each side owes a $16.1 million termination fee under the merger agreement, and the outside date is March 31, 2027. Closing is expected in the fourth quarter.
The filing leaves the special meeting date and record date blank, so the vote on the share issuance has no date yet. Standard BioTools shares closed at $0.69 at Friday's close.
